A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib (NSC 736511, IND 74019) or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non-Small Cell Lung Cancer.

Trial Profile

A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib (NSC 736511, IND 74019) or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non-Small Cell Lung Cancer.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs Pemetrexed (Primary) ; Sunitinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Sep 2012 Planned End Date changed from 1 Aug 2010 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 25 Jun 2012 Primary endpoint 'Progression-free-survival-rate' has not been met.
    • 05 Jun 2012 Results presented at the 48th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top